Viewing Study NCT06618456



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06618456
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: None
First Post: 2024-05-07

Brief Title: Hypnosis Induction and Height Experience in VR - Control Group Comparison and Three Sessions
Sponsor: None
Organization: None

Study Overview

Official Title: Hypnosis Induction and Height Experience in Virtual Reality - Comparison With Control Group and Investigation of the Effect of Three Sessions
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study attempts to test wether a VR-supported trance induction and a subsequent exposure to altitude in VR with hypnotic suggestions via Audio reduces acrophobia more than a control-group intervention without trance induction Furthermore the study attempts to test if three sessions of the interventions within three weeks can lead to a stronger reduction of acrophobia than only one session

Participants will be selected via an online survey according to their score on the Height Interpersonal Questionnaire HIQ At the start of the study participants will be screened by professional clinicians for any mental disorders In the laboratory they will undergo one of the two interventions in VR experimental group control group and complete questionnaires for three times within three weeks On a separate day within these three weeks they will be placed in a 30-minute trance to test their suggestibility
Detailed Description: Prior to the measurement those interested in the study will complete a screening questionnaire on acrophobia HIQ online Besides they will be asked if they ever had negative experiences with VR or hypnosis Only persons who do not report negative experiences with VR or hypnosis and who attain a HIQ score bigger than 29 will be invited to take part in the study At the first appointment in the laboratory a screening with SCID questions about disorders that would lead to exclusion is conducted On the basis of this second screening participants will be admitted to the study Failure to meet the criteria see eligibility section will exclude participants from the study At the start of the assessment session participants will complete a sociodemographic questionnaire and again the HIQ

Participants are randomly assigned to one of the two groups Based on group affiliation they either undergo a VR-supported trance induction or the same VR-program without the trance induction Then there is an automatic transition to the altitude confrontation Both groups receive the same VR altitude confrontation the only difference is that in the experimental group a tree is presented near the participant whereas in the control group a parasol is presented at the same position Thus the sentences that refer to the tree are changed in the audio of the control group The height is increased to a maximum of 60 metres Participants can stop the experiment at any time by pressing a button on a handheld joystick During the confrontation various events eg rising balloons generate additional altitude cues The duration of the confrontation is approximately 15 minutes Subsequently participants complete questionnaires about their fear of heights HIQ for a post-measurement of altitude anxiety and about their experience of presence IPQ and their experience of hypnotic depth SSTT Participants will undergo these questionnaires and the intervention three times within three weeks On a separate day within these three weeks they will be placed in a 30-minute trance and given the Harvard Group Scale of Hypnotic Susceptibility HGSHS to test their suggestibility

The total time required for the participants ist therefore approximately three hours and 15 minutes

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None